The PVS-RIPO trial is available for recurrent glioblastoma patients with only one tumor. The tumor must be surgically accessible; the size must be no smaller than 1 cm and no larger than 5.5 cm, and the tumor must be located at least 1 cm away from the ventricles. Prior exposure to bevacizumab (Avastin) is permitted. For further information please contact the Preston Robert Tisch Brain Tumor Center at Duke at (919) 684-5301.
http://www.cancer.duke.edu/btc/modules/Research3/index.php?i...
Note: most clinical trials have other requirements such as age, gender, health condition, failed/doing/discontinuing other treatments, so it requires some persisence and research.
See also: